LLS Children's Initiative

The LLS Children’s Initiative Latest News

The LLS Children’s Initiative is a $100 million multi-year effort to take on children’s cancer through every facet of our mission: Research, Patient Education and Support and Policy and Advocacy. 

The LLS Children’s Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care.

On this page you will find the latest updates on every aspect of the initiative.

 

Latest News

PRA Health Sciences Joins The Leukemia & Lymphoma Society on Glob...

September 3, 2020, Rye Brook, N.Y. and Raleigh, N.C. - The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences (NASDAQ: PRAH) announced today a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia. The new LLS PedAL (Pediatric Acute Leukemia) master clinical trial will test, simultaneously, multiple targeted therapies f...

LLS Announced a Collaboration with the National Cancer Institute...

June 17, 2020 (Rye Brook, NY)  -The Leukemia & Lymphoma Society (LLS) announced today a collaboration with the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) to launch a global precision medicine clinical trial for children with acute leukemia. The three organizations share a commitment to address the urgent need for new, more precise and more effective treatments for children ...

Forming a Global Collaboration

  As we put the essential pieces together to launch a major precision medicine clinical trial for children with acute leukemia – LLS PedAL - one of the most important aspects of this trial will be its global reach. This LLS-led trial, which will test targeted therapies in children with acute myeloid leukemia, and eventually other high-risk leukemias, will benefit not only children in the United States, ...

The LLS Children’s Initiative Makes Headlines

Recently, Gwen Nichols, MD, Chief Medical Officer at LLS, shared her perspectives with STAT News on the urgent need to bring the promise of precision medicine to children with cancer. “Children with cancer are not benefiting enough from the progress we are making,” writes Dr. Nichols. Here at LLS, we’re calling for a full-scale renaissance in pediatric drug development and care to address this pressing challeng...

Sailing in One Direction to End Childhood Cancer

In the treatment of children with acute myeloid leukemia “We have plateaued. The tools in our toolbox are all sledgehammers.” This grim assessment was how Dr. E. Anders Kolb, of Nemours/Alfred I DuPont Hospital for Children, characterized the state of treatment for children with this devastating form of leukemia. Dr. Kolb was among a group of pediatric oncologists to join The Leukemia & Lymphoma Soc...

Supporting The Next Generation of Research

A key component of The LLS Children’s Initiative is supporting cutting edge research to accelerate the most impactful pediatric cancer science worldwide. LLS has committed to more than doubling our funding of research grants to find safer and more effective therapies for children, teens and young adults with blood cancers.  The areas of focus include:  Harnessing the immune system to kill canc...

LLS PedAL: Precision Medicine for Children with Leukemia

As part of The LLS Children’s Initiative, LLS is working with a team of renowned pediatric oncologists to lay the groundwork for a global precision medicine master clinical trial to match children with relapsed acute leukemia to a targeted therapy based on the specific abnormalities driving their cancer. The goal of the LLS PedAL master clinical trial is to test multiple targeted therapies simultaneously at up t...